AMPE:NYE-Ampio Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.87

Change

+0.03 (+3.12)%

Market Cap

USD 0.16B

Volume

1.98M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.22 (+0.33%)

USD152.06B 24.03 2.70
BHVN Biohaven Pharmaceutical Holdin..

-0.52 (-0.58%)

USD5.40B N/A N/A
ADCT ADC Therapeutics SA

-0.05 (-0.14%)

USD2.74B -99,999.99 N/A
ZYME Zymeworks Inc

+0.79 (+1.65%)

USD2.19B 300.20 N/A
MYOV Myovant Sciences Ltd

+0.39 (+1.82%)

USD1.94B N/A N/A
RCUS Arcus Biosciences, Inc

-1.00 (-3.94%)

USD1.65B N/A N/A
CVM CEL-SCI Corporation

+0.21 (+1.71%)

USD0.47B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

-0.24 (-1.15%)

USD0.33B N/A N/A
IBIO iBio, Inc

-0.01 (-0.68%)

USD0.27B N/A N/A

ETFs Containing AMPE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.00% 75% C 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.00% 75% C 93% A
Trailing 12 Months  
Capital Gain 93.33% 85% B 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.33% 85% B 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 15.64% N/A N/A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.64% N/A N/A 85% B
Risk Return Profile  
Volatility (Standard Deviation) 37.88% N/A N/A 13% F
Risk Adjusted Return 41.30% N/A N/A 57% F
Market Capitalization 0.16B 59% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.87 22% F 28% F
Price/Book Ratio 14.85 22% F 5% F
Price / Cash Flow Ratio -10.15 62% D- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -165.48% 21% F 2% F
Return on Invested Capital -318.11% 14% F 0% N/A
Return on Assets -75.65% 18% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 16.48 10% F 2% F
Short Percent 10.52% 15% F 34% F
Beta 1.80 52% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.